3847-29-8 Erythromycin lactobionate, 610ug/mg AKSci E909
 
 
Loading Please Wait...
  E909    
Erythromycin lactobionate, 610ug/mg
 



IDENTITY
CAS Number:3847-29-8
MDL Number:MFCD01716346
MF:C49H89NO25
MW:1092.22
EINECS:223-348-7
SPECIFICATIONS & PROPERTIES
Physical Form:White to off-white powder
Melting Point:145-150°C
Long-Term Storage:Store long-term at -20°C

BIOLOGICAL INFO
Application(s):Antibiotic

REVIEW

 'Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the ''''P'''' or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the ''''A'''' or acceptor site to the ''''P'''' or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.'

REFERENCES
[1]Kanazawa S, Ohkubo T, Sugawara K: The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):799-803.
[2] Ogwal S, Xide TU: Bioavailability and stability of erythromycin delayed release tablets. Afr Health Sci. 2001 Dec;1(2):90-6.
[3] Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K: Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol. 2007 Jul;47(7):871-6.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of July 18, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Antibacterials, Macrolides


PubChem